Searched for
ZOFRAN
Undoing a night of overdoing it: These companies will come to your office to help cure the hangoverNurses stand ready to provide intravenous care to the dehydrated.- Aurobindo Pharmaceuticals gets USFDA nod for nausea injectionsThe injections are the generic equivalent of GlaxoSmithKline's Zofran injection, Aurobindo Pharma said.
- Aurobindo Pharma shares rise after USFDA nod for Ondansetron injectionsShares of Aurobindo Pharma moved higher in trade after the company got approval from the USFDA to manufacture and market Ondansetron inject...
- DRL net dips 68% on price pressure, writedownDr Reddy’s Laboratories (DRL) suffered a 68% fall in Q4 net profit ended March 2008, after writing down the intangible value of the product...
- Glenmark gets nod to sell Zofran generic in USGlenmark Pharmaceuticals has received final approval to market a generic version of GlaxoSmithKline’s popular anti-emetic drug Zofran, that...
- Glenmark gets USFDA nod to market cancer drugsGlenmark Pharmaceuticals says it has received the US Food and Drug Administration approval to market two of its cancer drugs.
- Foreign buys, new products pep up pharma sector: Buoyed by overseas acquisitions and new product launches in regulated markets, the pharma sector recorded exponential growth in the fourt...
- Dr Reddy’s logs Rs 325-crore net profit in Q4Hyderabad-Based Dr Reddy’s has crossed revenues of $1.5 billion or Rs 6,500 crore in 2006-07 against Rs 2,400 crore (FY06) piggybacking on ...
- Generic vs generic: Drug cos battle to protect turfGeneric drug makers, which have typically waged legal battles against innovator pharma giants, are now suing each other to protect their ma...
- Pharma may prove to be the Little Miss SunshineBuoyed by overseas acquisitions and strong growth in key international markets, pharma companies could see an overall 38% increase in net p...
- Windfall for cos eyeing US oncology marketWith anti-cancer blockbuster drugs set to go off-patent in the US in the next three to four years, generic players are gearing up to tap th...
- Dr Reddy’s Q3 net trebles, 9-mth revenue crosses $1bnDr Reddy’s Laboratories has gained entry into the $1-billion club with its nine months’ revenue of 2006-07.
- DRL's generic version of Zofran likely to generate Rs 200 cr in 6 monthsDr Reddy’s Labs’ (DRL) generic version of GlaxoSmithKline’s (GSK) Zofran could generate revenues of around Rs 200 crore ($45 million) in th...
- DRL gets US nod for multiple dosages of OndansetronPharmaceutical firm Dr Reddy's Laboratories Ltd has received approval from the US Food and Drug Administration to market Ondansetron Hydroc...
Load More- DRL net dips 68% on price pressure, writedown
